重磅!Nat Med报道HIV抗体临床实验获得成功

2017-01-20 佚名 生物谷

一个由洛克菲勒大学研究人员和科隆大学及德国感染研究中心的Florian Klein教授领导的研究团队在人体中检测了一个新的HIV中和抗体(10-1074)的效果,相关临床试验数据最近发表在《Nature Medicine》上。 过去几年里,研究人员发现了一些新的HIV中和抗体。“这些抗体作用很强大,可有效中和一系列不同的HIV病毒株,因此它们在发展HIV疫苗过程中发挥重要作用。”Klei

一个由洛克菲勒大学研究人员和科隆大学及德国感染研究中心的Florian Klein教授领导的研究团队在人体中检测了一个新的HIV中和抗体(10-1074)的效果,相关临床试验数据最近发表在《Nature Medicine》上。

过去几年里,研究人员发现了一些新的HIV中和抗体。“这些抗体作用很强大,可有效中和一系列不同的HIV病毒株,因此它们在发展HIV疫苗过程中发挥重要作用。”Klein教授说道。此外,通过与科隆大学医院传染病科及洛克菲勒大学的研究人员合作,Klein教授正在研究这些广谱中和性抗体是否可以用于治疗HIV感染。

广谱中和抗体10-1074可靶向HIV衣壳蛋白上的一个特殊结构。在这项研究中,研究人员发现病人对该抗体具有很好的耐受性,其药代动力学性质也很好。此外,研究人员发现该抗体在HIV感染者身上表现出了很高的抗病毒活性。研究团队还以此研究了耐药性HIV变异株的发展过程。“我们对HIV序列进行了全面分析,以确定HIV逃过抗体产生的选择压力的过程及机理。”该论文的共同第一作者之一Henning Gruell博士说道。

“这项研究在洛克菲勒大学和许多其他研究机构合作者的紧密合作下取得了成功。”Klein教授说道,他是德国的项目负责人,也是这篇论文的共同通讯作者之一。该研究团队正在计划进一步的临床实验以研究该抗体介导的免疫反应对HIV感染者的治疗效果,计划在春季进行接下来的临床实验。

原始出处:Antibody 10-1074 suppresses viremia in HIV-1-infected individuals,Marina Caskey et al, Nature Medicine (2017).DOI: 10.1038/nm.4268。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2036527, encodeId=73a4203652e10, content=<a href='/topic/show?id=8ebe8910d5' target=_blank style='color:#2F92EE;'>#HIV抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8910, encryptionId=8ebe8910d5, topicName=HIV抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Mon Mar 27 23:11:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881634, encodeId=6ca5188163475, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 21 08:11:00 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941549, encodeId=3dd119415490d, content=<a href='/topic/show?id=108022e76b3' target=_blank style='color:#2F92EE;'>#临床实验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22776, encryptionId=108022e76b3, topicName=临床实验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Tue Apr 25 17:11:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=173791, encodeId=100c1e3791ea, content=长见识了,厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Thu Feb 02 10:24:56 CST 2017, time=2017-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549020, encodeId=043e154902003, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sun Jan 22 05:11:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607256, encodeId=05ce160e256f5, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jan 22 05:11:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=171687, encodeId=dffe1e1687c5, content=长长见识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Sat Jan 21 00:11:52 CST 2017, time=2017-01-21, status=1, ipAttribution=)]
    2017-03-27 Homburg
  2. [GetPortalCommentsPageByObjectIdResponse(id=2036527, encodeId=73a4203652e10, content=<a href='/topic/show?id=8ebe8910d5' target=_blank style='color:#2F92EE;'>#HIV抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8910, encryptionId=8ebe8910d5, topicName=HIV抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Mon Mar 27 23:11:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881634, encodeId=6ca5188163475, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 21 08:11:00 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941549, encodeId=3dd119415490d, content=<a href='/topic/show?id=108022e76b3' target=_blank style='color:#2F92EE;'>#临床实验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22776, encryptionId=108022e76b3, topicName=临床实验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Tue Apr 25 17:11:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=173791, encodeId=100c1e3791ea, content=长见识了,厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Thu Feb 02 10:24:56 CST 2017, time=2017-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549020, encodeId=043e154902003, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sun Jan 22 05:11:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607256, encodeId=05ce160e256f5, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jan 22 05:11:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=171687, encodeId=dffe1e1687c5, content=长长见识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Sat Jan 21 00:11:52 CST 2017, time=2017-01-21, status=1, ipAttribution=)]
    2017-11-21 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=2036527, encodeId=73a4203652e10, content=<a href='/topic/show?id=8ebe8910d5' target=_blank style='color:#2F92EE;'>#HIV抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8910, encryptionId=8ebe8910d5, topicName=HIV抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Mon Mar 27 23:11:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881634, encodeId=6ca5188163475, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 21 08:11:00 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941549, encodeId=3dd119415490d, content=<a href='/topic/show?id=108022e76b3' target=_blank style='color:#2F92EE;'>#临床实验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22776, encryptionId=108022e76b3, topicName=临床实验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Tue Apr 25 17:11:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=173791, encodeId=100c1e3791ea, content=长见识了,厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Thu Feb 02 10:24:56 CST 2017, time=2017-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549020, encodeId=043e154902003, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sun Jan 22 05:11:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607256, encodeId=05ce160e256f5, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jan 22 05:11:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=171687, encodeId=dffe1e1687c5, content=长长见识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Sat Jan 21 00:11:52 CST 2017, time=2017-01-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2036527, encodeId=73a4203652e10, content=<a href='/topic/show?id=8ebe8910d5' target=_blank style='color:#2F92EE;'>#HIV抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8910, encryptionId=8ebe8910d5, topicName=HIV抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Mon Mar 27 23:11:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881634, encodeId=6ca5188163475, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 21 08:11:00 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941549, encodeId=3dd119415490d, content=<a href='/topic/show?id=108022e76b3' target=_blank style='color:#2F92EE;'>#临床实验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22776, encryptionId=108022e76b3, topicName=临床实验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Tue Apr 25 17:11:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=173791, encodeId=100c1e3791ea, content=长见识了,厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Thu Feb 02 10:24:56 CST 2017, time=2017-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549020, encodeId=043e154902003, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sun Jan 22 05:11:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607256, encodeId=05ce160e256f5, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jan 22 05:11:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=171687, encodeId=dffe1e1687c5, content=长长见识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Sat Jan 21 00:11:52 CST 2017, time=2017-01-21, status=1, ipAttribution=)]
    2017-02-02 wmu姿

    长见识了,厉害

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2036527, encodeId=73a4203652e10, content=<a href='/topic/show?id=8ebe8910d5' target=_blank style='color:#2F92EE;'>#HIV抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8910, encryptionId=8ebe8910d5, topicName=HIV抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Mon Mar 27 23:11:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881634, encodeId=6ca5188163475, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 21 08:11:00 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941549, encodeId=3dd119415490d, content=<a href='/topic/show?id=108022e76b3' target=_blank style='color:#2F92EE;'>#临床实验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22776, encryptionId=108022e76b3, topicName=临床实验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Tue Apr 25 17:11:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=173791, encodeId=100c1e3791ea, content=长见识了,厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Thu Feb 02 10:24:56 CST 2017, time=2017-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549020, encodeId=043e154902003, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sun Jan 22 05:11:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607256, encodeId=05ce160e256f5, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jan 22 05:11:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=171687, encodeId=dffe1e1687c5, content=长长见识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Sat Jan 21 00:11:52 CST 2017, time=2017-01-21, status=1, ipAttribution=)]
    2017-01-22 xxxx1054
  6. [GetPortalCommentsPageByObjectIdResponse(id=2036527, encodeId=73a4203652e10, content=<a href='/topic/show?id=8ebe8910d5' target=_blank style='color:#2F92EE;'>#HIV抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8910, encryptionId=8ebe8910d5, topicName=HIV抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Mon Mar 27 23:11:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881634, encodeId=6ca5188163475, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 21 08:11:00 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941549, encodeId=3dd119415490d, content=<a href='/topic/show?id=108022e76b3' target=_blank style='color:#2F92EE;'>#临床实验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22776, encryptionId=108022e76b3, topicName=临床实验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Tue Apr 25 17:11:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=173791, encodeId=100c1e3791ea, content=长见识了,厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Thu Feb 02 10:24:56 CST 2017, time=2017-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549020, encodeId=043e154902003, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sun Jan 22 05:11:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607256, encodeId=05ce160e256f5, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jan 22 05:11:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=171687, encodeId=dffe1e1687c5, content=长长见识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Sat Jan 21 00:11:52 CST 2017, time=2017-01-21, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2036527, encodeId=73a4203652e10, content=<a href='/topic/show?id=8ebe8910d5' target=_blank style='color:#2F92EE;'>#HIV抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8910, encryptionId=8ebe8910d5, topicName=HIV抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Mon Mar 27 23:11:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881634, encodeId=6ca5188163475, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 21 08:11:00 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941549, encodeId=3dd119415490d, content=<a href='/topic/show?id=108022e76b3' target=_blank style='color:#2F92EE;'>#临床实验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22776, encryptionId=108022e76b3, topicName=临床实验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Tue Apr 25 17:11:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=173791, encodeId=100c1e3791ea, content=长见识了,厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Thu Feb 02 10:24:56 CST 2017, time=2017-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549020, encodeId=043e154902003, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sun Jan 22 05:11:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607256, encodeId=05ce160e256f5, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jan 22 05:11:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=171687, encodeId=dffe1e1687c5, content=长长见识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Sat Jan 21 00:11:52 CST 2017, time=2017-01-21, status=1, ipAttribution=)]
    2017-01-21 laymankey

    长长见识了!

    0

相关资讯

Science子刊:鉴定出制造强大HIV抗体的人的免疫学特征

让HIV疫苗开发陷入混乱的主要问题之一就是为何一些人感染上这种病毒几年后制造出所需的抗体,但是HIV疫苗似乎不能够诱导相同的抗体反应。 来自美国杜克大学人类疫苗研究所的一个研究团队一直在努力阐明这个问题。通过分析100名HIV感染者---一半人的免疫系统最终制造出能够广泛中和HIV病毒的抗体,另外一半人的免疫系统不能够做到这一点,研究人员发现几个关键的免疫差异应当有助制定开发有效疫苗的指导手

NEJM:HIV抗体VRC01能抑制病毒反弹吗?

有效和广泛的中和抗体(bNAbs)对人类免疫缺陷病毒(HIV)会产生被动免疫,是HIV治疗和预防的潜在战略之一。我们试图确定,被动管理VRC01(bNAb靶向HIV CD4结合位点)能否预防或延迟停止抗逆转录病毒疗法(ART)后的血浆病毒反弹。 我们进行了两个开放标签试验(AIDS临床试验组[ACTG] A5340和国家健康研究院[NIH]15-I-0140)调查VRC01对中断ART治疗的